Stock GLPG GALAPAGOS NV
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Galapagos NV Nasdaq

Equities

GLPG

US36315X1019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
29.08 USD +0.59% Intraday chart for Galapagos NV -3.87% -28.46%
Apr. 08 Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024 CI
Mar. 28 Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says MT

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
GALAPAGOS NV Stock Galapagos NV
-28.46% 1.92B -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.42% 41.35B
B
LONZA GROUP AG Stock Lonza Group AG
+42.15% 40.38B
A
MODERNA, INC. Stock Moderna, Inc.
+1.97% 39.05B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-14.19% 26.67B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+1.82% 24.07B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.55% 18.36B
B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-4.07% 11.68B
C+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+21.36% 11.6B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.20% 11.15B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GLPG Stock
  4. GLPG Stock
  5. Ratings Galapagos NV